Leticia Toledo-Sherman
Corporate Officer/Principal bij LymphoSign, Inc.
Profiel
Leticia Toledo-Sherman has been Executive Director of Chemistry for LymphoSign, Inc. since August 2004.
Prior to joining LymphoSign, Inc, she was Director of Drug Design and Discovery for MDS Proteomics Inc. Dr. Toledo-Sherman worked for Kinetix Pharmaceuticals, Inc. She received a PhD in Organic Chemistry from The State University of New York.
Actieve functies van Leticia Toledo-Sherman
Bedrijven | Functie | Begin |
---|---|---|
LymphoSign, Inc.
LymphoSign, Inc. BiotechnologyHealth Technology LymphoSign, Inc. develops drugs for the cancer treatment. It also develops drugs acting on signaling pathways involved in the progression of acute leukemias, lymphomas and solid tumors. The company was founded by Chaim Roifman in 2000 and is headquartered in Markham, Canada. | Corporate Officer/Principal | 01-08-2004 |
Eerdere bekende functies van Leticia Toledo-Sherman
Bedrijven | Functie | Einde |
---|---|---|
MDS Proteomics, Inc. | Corporate Officer/Principal | - |
Kinetix Pharmaceuticals, Inc.
Kinetix Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Kinetix Pharmaceuticals develops selective protein kinase inhibitors which block disease-causing pathways resulting from aberrant protein kinase activity | Corporate Officer/Principal | - |
Opleiding van Leticia Toledo-Sherman
The State University of New York | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 3 |
---|---|
MDS Proteomics, Inc. | Commercial Services |
Kinetix Pharmaceuticals, Inc.
Kinetix Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Kinetix Pharmaceuticals develops selective protein kinase inhibitors which block disease-causing pathways resulting from aberrant protein kinase activity | Commercial Services |
LymphoSign, Inc.
LymphoSign, Inc. BiotechnologyHealth Technology LymphoSign, Inc. develops drugs for the cancer treatment. It also develops drugs acting on signaling pathways involved in the progression of acute leukemias, lymphomas and solid tumors. The company was founded by Chaim Roifman in 2000 and is headquartered in Markham, Canada. | Health Technology |